在心房的非药理性中风预防
Iñigo Anduaga1, Alessandro Affronti2, Pedro Cepas-Guillén1
1Cardiology Department, Institut Clínic Cardiovascular, Hospital Clínic de Barcelona, 08036 Barcelona, Spain.
Journal of clinical medicine
|September 9, 2023
概括
心房动 (AF) 增加了中风的风险. 左心房尾阻塞 (LAAO) 提供了抗凝药的非药物替代方案,用于预防AF患者的血栓和栓塞.
科学领域:
- 心脏病学 心脏病学
- 医疗器械 医疗器械
- 血栓形成研究研究
背景情况:
- 心房动 (AF) 是全球流行的一种心律失常,显著增加了中风和全身栓塞的风险.
- 血栓塞栓症的预防在AF管理中至关重要,口服抗凝药是主要治疗方法.
- 左心房附属体 (LAA) 是AF患者中血栓的常见来源.
研究的目的:
- 审查和综合现有关于外科手术和皮肤间左心房尾闭塞 (LAAO) 的证据.
- 评估LAAO作为一种非药物替代品,用于预防AF中的血栓栓塞.
- 提供LAAO技术和成果的全面概述.
主要方法:
- 对手术和皮肤间的LAAO手术现有文献进行系统审查.
- 对LAAO的疗效,安全性和患者选择数据的分析.
- 支持LAAO作为口服抗凝药的替代品的证据摘要.
主要成果:
- 无论是外科手术还是皮肤透的LAAO手术都已成为口服抗凝药的可行替代品.
- 这些方法旨在通过封闭LAA,即经常形成血栓的地方来降低中风和栓塞的风险.
- 证据支持LAAO在对抗凝血疗法有禁忌或不耐受的患者中使用.
结论:
- 左心房尾阻塞 (LAAO) 是一种重要的非药理学策略,可以降低心房的中风风险.
- 手术和皮肤透的LAAO都是长期抗凝药的确立替代品.
- 目前正在进行进一步的研究和数据合成,以完善LAAO的指示和技术.
相关概念视频
Atherosclerosis III: Management
12
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
12
Atherosclerosis IV: Nursing Management
21
Nursing management for a patient with arteriosclerosis involves a comprehensive approach focusing on lifestyle modification, disease monitoring, education, and symptomatic care. Here is an overview of effective nursing strategies:Assessment and Monitoring: Initial and ongoing assessments are crucial. Nurses must document the patient's medical history, including any hypertension, diabetes, hyperlipidemia, and other cardiovascular diseases. Assessments also cover family history and lifestyle...
21
Coronary Artery Disease IV: Preventive Measures
23
Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...
23
Venous Thrombosis III: Interprofessional Care
10
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
10
Dysrhythmias VI: Management of Dysrhythmias
19
Dysrhythmia management involves a multifaceted approach, incorporating pharmacological treatments, medical procedures, surgical interventions, lifestyle modifications, and patient education.Pharmacological ManagementAntiarrhythmic Drugs:Class I (Sodium Channel Blockers): This class includes quinidine and procainamide, which reduce the speed of impulse conduction in the heart, stabilize the cardiac membrane, and control arrhythmias. Quinidine and procainamide are Class IA agents that prolong the...
19
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
1.2K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
1.2K


